A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

NCT02214225 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3484

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza, Human

Interventions

BIOLOGICAL: Quadrivalent Influenza Vaccine (QIV)
BIOLOGICAL: Trivalent Influenza Vaccine (TIV-1)
BIOLOGICAL: Trivalent Influenza Vaccine (TIV-2)

Sponsor

Seqirus